Jeff Yass’s Cartesian Therapeutics RNAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-20,400
Closed -$213K – 14373
2026
Q2
$213K Buy
+20,400
New +$151K ﹤0.01% 11813
2026
Q1
– Sell
-17,300
Closed -$125K – 13970
2025
Q4
$125K Buy
17,300
+700
+4% +$5.66K ﹤0.01% 11322
2025
Q3
$170K Buy
+16,600
New +$187K ﹤0.01% 11154
2022
Q4
– Sell
-653
Closed -$32K – 13490
2022
Q3
$32K Buy
653
+150
+30% +$8.24K ﹤0.01% 12425
2022
Q2
$20K Buy
503
+40
+9% +$1.19K ﹤0.01% 12366
2022
Q1
$17K Sell
463
-10
-2% -$626 ﹤0.01% 12669
2021
Q4
$46K Sell
473
-70
-13% -$7.53K ﹤0.01% 12593
2021
Q3
$68K Sell
543
-414
-43% -$50K ﹤0.01% 12239
2021
Q2
$120K Sell
957
-4,053
-81% -$483K ﹤0.01% 11991
2021
Q1
$680K Buy
5,010
+3,980
+386% +$494K ﹤0.01% 8747
2020
Q4
$94K Buy
1,030
+363
+54% +$31.5K ﹤0.01% 10522
2020
Q3
$50K Buy
+667
New +$51.1K ﹤0.01% 10199

Other funds holding RNAC

Jeff Yass's RNAC Position: Q3 2026 in Review

Jeff Yass opened a new position in Cartesian Therapeutics (RNAC) in Q3 2026: 27,007 shares worth $195K. The stake represents ﹤0.01% of the portfolio and ranks #12002 among its holdings. This is a return to the name: Jeff Yass previously reported a position in RNAC as recently as Q3 2025.

Jeff Yass first reported a position in RNAC in Q1 2017 and has held it in 22 quarters since. The position peaked at $1.17M in Q1 2023. 95 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

  • Jeff Yass held 27,007 shares of Cartesian Therapeutics worth $195K as of Q3 2026.
  • Cartesian Therapeutics was a new Jeff Yass position in Q3 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #12002 holding.
  • Jeff Yass first reported a position in Cartesian Therapeutics in Q1 2017 and has held it in 22 quarters since.
  • Jeff Yass's Cartesian Therapeutics position peaked at $1.17M in Q1 2023.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.